Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

19/10/2015 - 2 minutes

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment.

g720174g54z74Affimed Therapeutics is a NASDAQ-listed biotech which is trialling immunotherapies for cancers such as Hodgkin’s Lymphoma. Affimed’s candidates are being developed in the field of immuno-oncology, which broadly looks to innovate new monoclonal antibody types to stimulate an immune response against tumor cells.

Affimed’s proprietary next-generation antibodies are bi-specific (binding to multiple target sites at once), and are so-called TandAbs due to their tandem structure. TandAbs are designed to direct and establish a bridge between either NK-cells or T-cells with the tumor cells, in order to trigger a signal cascade that leads to the destruction of cancerous types.

Affimed’s leading candidate, AFM13, is in phase II trials for Hodgkin’s lymphoma,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!